Kwality Pharmaceutical Secures Bleomycin Registration in Mexico, Expands Oncology Portfolio Aug 18, 2025
Kwality Pharmaceuticals has obtained product registration for Bleomycin 15 IU per vial in Mexico, expanding its oncology portfolio in regulated markets. The company expects to generate approximately 1.00 million USD in the first year of sales, with supplies commencing before the end of Q2FY26. Bleomycin is used to treat various cancers including Hodgkin's lymphoma, testicular cancer, and certain squamous cell carcinomas. This approval strengthens Kwality's global presence and commitment to delivering quality oncology products worldwide.
Kwality Pharmaceuticals Board Approves Key Reappointments and Sets 42nd AGM Date Aug 16, 2025
Kwality Pharmaceuticals Reports Robust 39.8% Revenue Growth in Q1 FY26 Aug 11, 2025
Kwality Pharmaceuticals Reshuffles Board, Appoints New Independent Director Jul 26, 2025
Kwality Pharmaceuticals Reports Q4 EBITDA Growth and Triple-Digit Profit Surge May 19, 2025